References
Argyriou AA, Iconomou G, Kalofonos HP (2008) Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 112(5):1593–1599
Wang A, Duan Q, Liu X, Ding K, Han Y, Zhu W et al (2012) (Bortezomib plus lenalidomide/thalidomide)- vs (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials. Ann Hematol 91(11):1779–1784
McCool FD, Tzelepis GE (2012) Dysfunction of the diaphragm. N Engl J Med 366(10):932–942
Dangoumau J, Begaud B (1982) [Imputability of drug side effects]. Nouv Presse Med 11(40):2995–2997
Gupta S, Pagliuca A, Devereux S, Mufti GJ, Schey S (2006) Life-threatening motor neurotoxicity in association with bortezomib. Haematologica 91(7):1001
Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP et al (2007) Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 110(5):1042–1049
Caravita T, Petrucci MT, Spagnoli A, Siniscalchi A, Offidani M, Federico V et al (2007) Neuropathy in multiple myeloma patients treated with bortezomib: a multicenter experience. Blood 110(11):280B
Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J et al (2005) Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 129(6):776–783
Conflict of interest
The authors state that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nizeica, V., Collet, P. & Marotte, H. Bortezomib induced a phrenic palsy in a multiple myeloma patient. Ann Hematol 92, 1135–1136 (2013). https://doi.org/10.1007/s00277-013-1687-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-013-1687-3